tutorial

PEComa Care Tech Platform Monitoring Guide 2026

"A comprehensive guide to monitoring digital health platforms supporting PEComa care, covering mTOR pathway biomarker routing from molecular testing, everolimus/sirolimus toxicity surveillance, TSC mutation–driven treatment decision support, rare tumor registry workflows, and disease progression imaging automation."

PEComa Care Tech Platform Monitoring Guide 2026

Overview

Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms defined by their distinctive morphology — epithelioid cells with clear to eosinophilic granular cytoplasm arranged around blood vessels — and their consistent immunoreactivity for both melanocytic markers (HMB-45, Melan-A) and smooth muscle markers (SMA, desmin). PEComas form a family that includes angiomyolipoma (AML), lymphangioleiomyomatosis (LAM), and clear cell "sugar" tumor of the lung, alongside the broader group of soft tissue and visceral PEComas that constitute the primary oncologic management challenge. Malignant PEComa is exceptionally rare, with an estimated incidence in the low hundreds annually in the United States, making it one of the most challenging rare sarcoma subtypes to manage from both clinical and informatics perspectives.

The 2026 treatment landscape for malignant PEComa is shaped decisively by the discovery that the majority of cases harbor mutations or inactivations in TSC1 or TSC2, the tumor suppressor genes that regulate the mTOR signaling pathway. The AMPECT trial established nab-sirolimus (ABI-009) as the first FDA-approved therapy specifically for malignant PEComa, with objective response rates near 39% and disease control rates exceeding 70% in TSC1/TSC2-altered tumors. Conventional mTOR inhibitors (everolimus, temsirolimus) also demonstrate activity based on retrospective series. For patients without TSC alterations, the treatment pathway is less defined and may involve anthracycline-based regimens used in other soft tissue sarcomas, or enrollment in clinical trials targeting alternative molecular vulnerabilities.

Care technology platforms supporting PEComa must navigate the compound challenges of extreme rarity, molecular stratification by TSC mutation status, and mTOR inhibitor–specific toxicity management. Systems must ensure molecular test ordering and results routing for TSC1/TSC2, drive treatment decision logic based on alteration status, monitor the distinctive toxicity profile of mTOR inhibitors (pneumonitis, stomatitis, hyperglycemia, hyperlipidemia), support enrollment in rare tumor registries and clinical trials, and schedule imaging surveillance appropriate for an unpredictable disease with variable growth kinetics.

Care Technology Landscape

Molecular Testing and Results Routing Platforms — TSC1/TSC2 mutation status is the central molecular datum driving treatment selection in malignant PEComa. Laboratory information systems (LIS) and molecular diagnostic platforms must support structured reporting of TSC1 (chromosome 9q34) and TSC2 (chromosome 16p13) pathogenic variants, VUS classifications, and allele-specific loss-of-heterozygosity findings. Results must route from the LIS to the oncology information system (OIS) with fields that downstream CDS engines can parse for mTOR inhibitor eligibility.

Rare Tumor Clinical Decision Support — Generic oncology CDS platforms designed for common tumor types require customization or overlay modules to handle PEComa. Platforms such as Epic Beacon with custom treatment plan templates, or rare-disease CDS overlays from vendors like Flatiron or Tempus, must be configured to surface the nab-sirolimus indication when TSC-altered malignant PEComa is confirmed, and to flag non-TSC-altered cases for clinical trial enrollment pathways.

mTOR Inhibitor Toxicity Monitoring Systems — The mTOR inhibitor class carries a characteristic toxicity profile distinct from cytotoxic chemotherapy or immunotherapy. Platforms must be configured for everolimus/sirolimus/nab-sirolimus–specific monitoring: oral mucositis grading workflows, pulmonary function and CT-based pneumonitis detection, fasting glucose and lipid panel surveillance, renal function monitoring, and CBC for cytopenias. PRO platforms calibrated for mTOR inhibitor symptoms significantly improve early detection of dose-limiting toxicities.

Rare Tumor Registry Integration — PEComa's rarity demands systematic data capture for research and quality improvement. Platforms must support bidirectional integration with rare sarcoma registries such as the SARC consortium databases, NCI CONNECT rare tumor registry, and institution-specific tumor boards. Structured data export in FHIR R4 or HL7 format for registry submission must be validated and monitored for completeness.

Imaging Surveillance and Response Assessment Platforms — PEComa response to mTOR inhibitors often manifests as tumor density reduction on CT (Choi criteria) rather than dimensional shrinkage alone (RECIST). Radiology information systems must support Choi criteria documentation and surfacing alongside standard RECIST measurements to avoid spurious progression calls based on size alone.

Key Monitoring Metrics

TSC1/TSC2 Molecular Testing Workflows

Test Ordering and Turnaround

  • TSC1/TSC2 molecular panel ordered at time of malignant PEComa diagnosis: ordering compliance rate (target: > 95%)
  • Tumor specimen submitted with adequate tissue for molecular analysis: specimen adequacy rate
  • Molecular panel turnaround time from specimen receipt to report sign-out: median and 90th percentile (target median ≤ 14 days for next-generation sequencing)

Results Routing and Structuring

  • TSC alteration status appearing in OIS structured field within 4 hours of LIS sign-out: routing success rate
  • VUS classifications flagged for multidisciplinary variant review: VUS escalation rate
  • Cases with TSC alteration correctly triggering nab-sirolimus eligibility flag in CDS: algorithmic trigger rate

Reflex Testing

  • IHC for HMB-45 and SMA ordered on all suspected PEComa specimens prior to molecular testing: reflexive order compliance
  • Negative or inconclusive IHC results triggering electron microscopy or additional immunopanel: escalation compliance rate

mTOR Inhibitor Toxicity Surveillance

Pneumonitis Monitoring

  • CT chest ordered at baseline and every 2 cycles per protocol: order compliance rate
  • Radiologist CT chest reports reviewed by oncology within 3 business days: review timeliness rate
  • Grade ≥ 2 radiologic pneumonitis (bilateral ground-glass or consolidation) generating oncology alert within 4 hours of report sign-out: alert rate
  • Patients with pneumonitis receiving dose modification or drug hold documented in treatment plan: response documentation rate

Metabolic Surveillance

  • Fasting glucose and lipid panel resulted within 1 week of cycle start: order compliance rate
  • Fasting glucose > 250 mg/dL or triglycerides > 500 mg/dL generating pharmacist notification: threshold alert rate
  • Hyperglycemia management plan (metformin initiation, dietary referral, endocrinology consult) documented within 5 business days of threshold breach: management compliance rate
  • HbA1c ordered every 3 cycles for patients on mTOR inhibitor with baseline diabetes: monitoring compliance

Stomatitis and Mucositis Grading

  • PRO mucositis survey completion rate per cycle for patients on nab-sirolimus or everolimus (target: > 80%)
  • Grade ≥ 2 stomatitis PRO report triggering nursing triage contact within 48 hours: alert generation rate
  • Steroid mouth rinse prescription issued at treatment initiation per prophylaxis protocol: prophylaxis compliance rate
  • Grade 3 stomatitis events resulting in dose modification documented in treatment record: dose modification compliance

Renal Function and Cytopenias

  • Creatinine and CBC resulted per cycle: order compliance rate
  • Creatinine > 1.5× baseline or ANC < 1.0 generating pharmacist review alert: threshold detection rate

Rare Tumor Registry Enrollment and Data Submission

Enrollment Tracking

  • Malignant PEComa cases identified by tumor registry query within 30 days of diagnosis confirmation: case ascertainment rate
  • Eligible patients offered enrollment in rare tumor registry or clinical trial: offer documentation rate (target: 100%)
  • Patients enrolled in SARC or NCI CONNECT registry: enrollment rate and cumulative cohort size

Data Completeness and Export

  • Required registry data elements (histopathology, molecular, treatment, outcomes) populated: completeness rate per field (target: > 90%)
  • Registry data exports completing without error on monthly schedule: export success rate
  • FHIR bundle validation errors flagged for informatics remediation: error detection and resolution rate

Imaging Response Assessment (RECIST and Choi)

Dual-Criteria Measurement

  • Baseline CT measurements captured in both RECIST and Choi (density HU) format: dual-capture compliance rate
  • Follow-up scans assessed with Choi criteria for patients on mTOR inhibitors: Choi assessment rate
  • Discordant RECIST progression / Choi response cases flagged for multidisciplinary tumor board review: discordance escalation rate

Schedule Compliance

  • Surveillance CT completed within ±7 days of planned 8-week interval: on-time completion rate (target: > 88%)
  • Patients overdue > 14 days triggering automated scheduling outreach: outreach automation rate
  • Post-response scans continued at 12-week intervals per year-2 surveillance protocol: interval compliance

Platform Setup

Observability Architecture for PEComa Platforms

Instrument platform components with Prometheus-compatible exporters:

# Prometheus scrape config for PEComa care platforms
scrape_configs:
  - job_name: molecular_routing_pecoma
    static_configs:
      - targets: ['lis-router.internal:9090']
    scrape_interval: 30s
    metric_relabel_configs:
      - source_labels: [tumor_type]
        regex: 'pecoma|perivascular_epithelioid'
        action: keep

  - job_name: mtor_toxicity_surveillance
    static_configs:
      - targets: ['toxicity-monitor.internal:9090']
    scrape_interval: 30s

  - job_name: rare_tumor_registry
    static_configs:
      - targets: ['registry-integration.internal:9090']
    scrape_interval: 120s

  - job_name: imaging_response_assessment
    static_configs:
      - targets: ['radiology-bridge.internal:9090']
    scrape_interval: 60s

TSC Alteration Routing Canary

Validate end-to-end molecular result propagation with a synthetic test:

# Pseudocode: TSC alteration routing canary
def run_tsc_routing_canary():
    test_patient_id = "CANARY-PECOMA-001"
    inject_molecular_report(
        patient_id=test_patient_id,
        tumor_type="malignant_pecoma",
        gene="TSC2",
        variant="c.4639C>T (p.Arg1547*)",
        classification="pathogenic"
    )
    start = time.now()
    ois_field = poll_for_ois_field(
        patient_id=test_patient_id,
        field="tsc_alteration_status",
        timeout=14400  # 4 hours
    )
    latency = time.now() - start
    metrics.record("tsc_routing_latency_seconds", latency)
    if ois_field is None:
        page_on_call("PEComa canary: TSC alteration not routed to OIS within 4-hour SLA")
    cds_flag = check_cds_recommendation(
        test_patient_id,
        includes="nab_sirolimus_eligible"
    )
    if not cds_flag:
        alert_informatics_team("PEComa canary: nab-sirolimus eligibility flag not surfaced in CDS")

mTOR Pneumonitis Alert Trigger

-- Flag CT chest reports containing pneumonitis language for PEComa patients on mTOR inhibitors
CREATE TRIGGER mtor_pneumonitis_flag
AFTER INSERT ON radiology_reports
FOR EACH ROW
WHEN NEW.modality = 'CT'
  AND NEW.body_region = 'chest'
  AND NEW.report_text ILIKE '%ground-glass%'
  AND EXISTS (
    SELECT 1 FROM active_treatments
    WHERE patient_id = NEW.patient_id
      AND drug_class = 'mtor_inhibitor'
      AND tumor_type = 'pecoma'
  )
EXECUTE PROCEDURE create_pneumonitis_oncology_alert(
  NEW.patient_id,
  NEW.report_id,
  priority := 'P1'
);

Monitor alert generation latency; SLA is within 4 hours of report sign-out.

Registry Export Health Monitor

# Pseudocode: monthly registry export validator
def validate_registry_export():
    export_result = trigger_registry_export(
        registry="sarc_consortium",
        tumor_type="pecoma",
        period="monthly"
    )
    if export_result.status != "success":
        alert_informatics_team(
            f"PEComa registry export failed: {export_result.error}"
        )
    completeness = calculate_field_completeness(export_result.records)
    for field, rate in completeness.items():
        metrics.record(f"registry_completeness_{field}", rate)
        if rate < 0.90:
            create_jira_ticket(
                project="ONC-INFORMATICS",
                title=f"PEComa registry field completeness below 90%: {field}",
                priority="P3"
            )

Alerting Strategies

Severity Tiering

P1 — Immediate Clinical Impact

  • LIS-to-OIS molecular routing pipeline offline; TSC alteration results not propagating
  • mTOR inhibitor toxicity alert system down; pneumonitis CT flag generation failing
  • Stomatitis grade 3–4 PRO report not triggering nursing triage contact
  • Grade ≥ 3 metabolic toxicity (glucose > 500, triglycerides > 1000) not generating pharmacist alert within 2 hours

P2 — Degraded Operation

  • TSC alteration routing latency exceeding 8 hours for > 5% of cases
  • Choi criteria assessment missing for > 15% of mTOR inhibitor follow-up scans
  • Registry export completeness dropping below 85% on consecutive monthly runs
  • Imaging surveillance overdue rate exceeding 12% of active PEComa cohort
  • PRO completion rate dropping below 70% week-over-week for mTOR inhibitor patients

P3 — Quality and Compliance

  • VUS variants not escalated to variant review board within 30 days: backlog item
  • Rare tumor registry enrollment offer not documented for eligible new diagnoses: audit ticket
  • Choi/RECIST discordance not escalated to tumor board within 14 days: quality gap

On-Call Escalation

Define a PEComa/rare sarcoma on-call structure:

  • Clinical informatics engineer (primary for P1 routing and alert system failures)
  • Oncology pharmacist (for out-of-hours mTOR toxicity threshold alerts)
  • Sarcoma APP or rare tumor clinic coordinator (for P1 clinical escalation and patient-facing triage)

Notification Channels

  • P1: PagerDuty page + SMS to primary and secondary on-call simultaneously
  • P2: Slack #pecoma-rare-tumor-informatics channel + email to oncology informatics lead
  • P3: Automated JIRA ticket to oncology informatics backlog queue

Conclusion

PEComa's molecular architecture — almost universally driven by TSC1/TSC2 inactivation and mTOR pathway dysregulation — makes it one of the rare sarcoma subtypes where targeted therapy is not aspirational but established and FDA-approved. Care technology platforms supporting malignant PEComa must be tuned to this biology: routing TSC alteration results from molecular labs with speed and fidelity, triggering nab-sirolimus eligibility decision support, managing the distinctive mTOR inhibitor toxicity profile including pneumonitis and stomatitis with calibrated surveillance workflows, supporting rare tumor registry participation to advance the evidence base, and applying dual RECIST and Choi imaging assessment to avoid erroneous progression calls.

Engineering teams responsible for PEComa informatics should prioritize the LIS-to-OIS molecular routing canary, automated CT pneumonitis flagging, and registry export health monitoring. These systems, operating reliably at scale, transform the challenge of managing an extremely rare disease into a reproducible, data-driven workflow that extends and improves care for one of the most molecularly defined rare sarcomas in clinical practice in 2026.

Monitor your app with Vigilmon

Free plan — 5 monitors, no credit card required. Up and running in 60 seconds.

Start free →
← Back to all articles